Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. - Wikidata - awgldk - TriplyDB

Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.

Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.

http://www.wikidata.org/entity/Q44165186

about

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene.Update on Sclerosing Cholangitis in Critically Ill Patients Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer Sulphatation does not appear to be a protective mechanism to prevent oxysterol accumulation in humans and mice A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography.The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice.Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice ABCB4 missense mutations D243A, K435T, G535D, I490T, R545C, and S978P significantly impair the lipid floppase and likely predispose to secondary pathologies in the human population.The Impact of Sterile Inflammation in Acute Liver Injury.Ursodeoxycholic acid treatment of vanishing bile duct syndromes.Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice.Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.Biliary physiology and disease: reflections of a physician-scientist.Role for hedgehog pathway in regulating growth and function of invariant NKT cells.Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis Treatment of autoimmune liver disease: current and future therapeutic options.Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.Gallstone disease.Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.TRAIL-producing NK cells contribute to liver injury and related fibrogenesis in the context of GNMT deficiency.Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice.Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis.24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.Genetic cholestasis, causes and consequences for hepatobiliary transport.Primary sclerosing cholangitis--the arteriosclerosis of the bile duct?Cholestasis protects the liver from ischaemic injury and post-ischaemic inflammation in the mouse Fibrates and cholestasis Characterization of animal models for primary sclerosing cholangitis (PSC).Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.Novel insight into mechanisms of cholestatic liver injury.Experimental models of liver fibrosis Bile Acid-Induced Toxicity in HepaRG Cells Recapitulates the Response in Primary Human Hepatocytes Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis.Critical Factors in the Assessment of Cholestatic Liver Injury In Vitro.

P2860

Q24655731-AC59D25A-07BF-4016-B36D-705F0E5E1402 Q24679309-2EA2B1D6-EF2D-4E79-A06E-EAF7EEB98CEB Q26782875-AD09D817-E093-4ABF-A918-7F2359230D0D Q27322930-1288C25E-45E3-4C4C-A0ED-4A947B97801F Q28534492-7E3ACCFF-97BC-42ED-AC03-F8D5973F4B03 Q30479829-41686F78-6FD0-4446-8421-B7C4FBB6AAB3 Q30535328-9D339DE0-2581-44E8-B136-A0C7181E0027 Q30560951-52C4AB5E-72EB-4728-9C2D-BCB72F02336A Q30613139-74B77C68-F1F8-44AE-8C83-2758906557FA Q33725965-F3038346-E6CC-4604-8CAB-2E928F596776 Q33744692-753A151E-3D6A-45B8-B6AC-72C67FD9C799 Q33754301-DD086C20-FC8D-4161-AC0D-D7B1095EEC7C Q33844494-CDC3ECFB-FDD2-435D-8F84-C6AE223FA4DB Q33847610-26959E74-039D-46F2-8E07-2CB2992DBFC8 Q33866782-174938B5-4F53-4D58-9002-16C092FF393A Q34037360-5125E68F-1F17-4006-8E2D-217CA85F50B5 Q34083354-E3EFDC4C-08D5-489F-A27A-2DFC2C526C03 Q34108895-2107C34C-2C5A-4075-97FF-6CAB09C9213F Q34247943-1B00CDDE-F152-4A70-B6CA-2C8FE8503BC6 Q34287861-B4B31967-2B4D-4A9A-B878-C0D95388E266 Q34342199-D89D1BBA-9A34-4F84-B3A7-37B44D97DC02 Q34479345-D93AE7F1-4D75-4D48-B0FA-486847463D47 Q34634193-25DD42BB-59A8-486A-A701-213E2F67A1C1 Q34752957-2DE64662-AE33-4F7C-89C6-7E145082A4FB Q35027678-FE5F72F2-6BBC-4916-9458-AE6277A5258B Q35087943-E238095C-371D-4FB9-8A49-9A2E964666D1 Q35181443-DD318392-D80F-4330-ADFE-D8E9A6441BE4 Q35201779-2273D24A-EEAF-4810-968A-2D798320B9C1 Q35621917-726FC3D2-0CC3-4A71-96D1-14ABFA932171 Q35632527-A04F92BC-81A5-47F9-AD8E-5D581970ED44 Q35761225-20C4DF87-9309-4E46-B203-2EC2FD530302 Q35889448-6F5B0EF7-8339-4211-8972-7F91CD633636 Q35896870-C28D568B-C25C-4F37-B1A4-6D5625F57B85 Q36197335-FCFA3D39-5585-4C8D-B580-2368C6523C41 Q36285749-D2C3C261-B4EA-425C-B5BD-CBD643F8D125 Q36442525-E1F05C4D-4A71-4590-95FD-BF0AA75A2707 Q36464118-EE8A6318-1471-4125-BE81-FDD82B7693AD Q36495172-F6EF6E53-B80A-4CFB-8A0E-1E4CCDCF0E38 Q36606886-87002120-250D-4BAB-8257-97CA86CB621D Q36614256-D564F2C0-A05C-4E77-BF77-9169F397FDEE

P2860

Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.

http://www.wikidata.org/entity/Q44165186

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Ursodeoxycholic acid aggravate ...... ia disruption of cholangioles.

@en

Ursodeoxycholic acid aggravate ...... ia disruption of cholangioles.

@nl

type

label

Ursodeoxycholic acid aggravate ...... ia disruption of cholangioles.

@en

Ursodeoxycholic acid aggravate ...... ia disruption of cholangioles.

@nl

prefLabel

Ursodeoxycholic acid aggravate ...... ia disruption of cholangioles.

@en

Ursodeoxycholic acid aggravate ...... ia disruption of cholangioles.

@nl

P1433

Q44165186-B2845536-8FF0-405F-80E1-4AF0B3524A48

P1476

Q44165186-68619592-1E23-4920-A885-746AE62D84D6

P2093

Q44165186-07E2119D-E92C-48F9-AFD2-C64BB8E84313

Q44165186-15D2182E-408E-4226-95DF-D4F8FAA1E25D

Q44165186-1E1F0D17-1DC4-4220-B71E-654BD70D5D98

Q44165186-2ACA0732-AE30-4515-AC05-427FFEC6913A

Q44165186-6A13307B-5730-4B80-8094-DF41D7F24ACA

Q44165186-83337103-A782-4F84-A3B5-6ED74138CCEF

Q44165186-B6E83D08-7381-4988-91A0-C1CA0B1B9E94

Q44165186-CBFE3886-AA77-4DC9-932E-0D7980441B06

Q44165186-F55C59EA-ABA1-4216-8C84-2B688A21E468

P304

Q44165186-BE57904D-F309-47F7-A14D-84AB3E6EB318

P31

Q44165186-7198EC38-ADAD-4904-859A-E4DC393727F1

P356

Q44165186-F788A818-5500-4BFD-927C-67EFBA1407A6

P407

Q44165186-D0D8D566-284A-475C-9EC0-AD14A23E909A

P433

Q44165186-6E606AEC-29F5-461B-AA27-5F22B6662488

P478

Q44165186-4DFB6AC3-6695-4D06-9C81-E277B8BABC41

P50

Q44165186-3A0057C6-E07D-4505-B76C-23FA2C74DE48

Q44165186-CF8A3763-060A-4013-97A3-947F0E716B87

P577

Q44165186-CDB5F704-792C-48C3-A98D-292793A57F10

P698

Q44165186-72423E97-460E-494E-A285-D87D61E3ABC9

P921

Q44165186-A834FDBF-7B3B-44E8-9AC8-A0662C8CC2C1

P356

GAST.2002.35948

P1433

Gastroenterology

P1476

Ursodeoxycholic acid aggravate ...... ia disruption of cholangioles.

@en

P2093

Andrea Fuchsbichler

http://www.w3.org/2001/XMLSchema#string

Andreas H Weiglein

http://www.w3.org/2001/XMLSchema#string

Conny Stumptner

http://www.w3.org/2001/XMLSchema#string

Frank Lammert

http://www.w3.org/2001/XMLSchema#string

Hanns-Ulrich Marschall

http://www.w3.org/2001/XMLSchema#string

Helmut Denk

http://www.w3.org/2001/XMLSchema#string

Michael Trauner

http://www.w3.org/2001/XMLSchema#string

Oleksiy Tsybrovskyy

http://www.w3.org/2001/XMLSchema#string

Peter Fickert

http://www.w3.org/2001/XMLSchema#string

P304

1238-1251

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/GAST.2002.35948

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12360485

http://www.w3.org/2001/XMLSchema#string

P921